Positive top-line results for bimekizumab in second phase 3 psoriatic arthritis study
UCB plans to submit regulatory applications in Q3 2022
UCB plans to submit regulatory applications in Q3 2022
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
Subscribe To Our Newsletter & Stay Updated